DR. CHARLES LEWIS MAURER MD NPI 1386675999

NPI Details

DR. Charles Lewis Maurer, MD is a hematology and oncology internal medicine in Fredericksburg, VA with 31 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Charles Lewis Maurer, MD NPI is 1386675999. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4501 EMPIRE COURT
FREDERICKSBURG, VA
ZIP 22408
Phone: (540) 371-0079
Fax: (540) 371-4254

The NPI 1386675999 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Magnesium level (HCPCS:83735)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Phosphate level (HCPCS:84100)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Unclassified drugs (HCPCS:J3490)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Collection of blood sample from implanted device (HCPCS:36591)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Prealbumin (protein) level (HCPCS:84134)
• Urinalysis, manual test (HCPCS:81002)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Uric acid level, blood (HCPCS:84550)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report (HCPCS:93000)
• Vitamin d-3 level (HCPCS:82306)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Drawing of blood for a medical problem (HCPCS:99195)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Stool analysis for blood, by peroxidase activity (HCPCS:82272)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of influenza virus vaccine (HCPCS:G0008)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)

The enumeration date for this NPI number is 7/5/2006 and was last updated on 7/21/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.